Global Information
회사소개 | 문의

난관암 : 파이프라인 제품 분석

Fallopian Tube Cancer - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 10월 상품 코드 229740
페이지 정보 영문 1103 Pages
가격
US $ 2,000 ₩ 2,287,800 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,575,600 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,863,400 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


난관암 : 파이프라인 제품 분석 Fallopian Tube Cancer - Pipeline Review, H2 2018
발행일 : 2018년 10월 페이지 정보 : 영문 1103 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

난관암이란 난관(나팔관 : 난소와 자궁을 연결하는 관)에 발병하는 암으로, 매우 드물게 발병합니다. 일반적인 증상으로 부정출혈(특히 폐경 후), 복부 통증 및 압박감, 비정상적(백색/투명/분홍색) 질분비물, 골반강내 종괴 등을 들 수 있으며, 환자의 2/3를 차지하고 있습니다. 일반적으로 암세포가 인체의 다른 부분(난소, 자궁내막 등)에서 난관으로 전이함으로써 발병합니다. 난소암의 치료법은 연령 및 출산 의사, 종양의 종류·병기에 따라 다릅니다. 일반적으로 화학요법 후에 외과 수술이 시행됩니다.

세계 각국에서의 난관암(나팔관암) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향 및 임상시험 각 단계의 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

목차

서론

난관암 개요

치료제 개발

난관암 : 치료제 평가

난관암 치료제 개발 참여 기업

약제 프로파일

난관암 치료제 : 개발 휴지 상태인 제품

난관암 치료제 : 개발이 중지된 제품

난관암 관련 제품 개발 마일스톤

부록

도표

LSH 17.06.05

List of Tables

  • Number of Products under Development for Fallopian Tube Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Fallopian Tube Cancer - Pipeline by AbbVie Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018
  • Fallopian Tube Cancer - Pipeline by AiVita Biomedical Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Aldeyra Therapeutics Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Altor BioScience Corp, H2 2018
  • Fallopian Tube Cancer - Pipeline by Amgen Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2018
  • Fallopian Tube Cancer - Pipeline by Astellas Pharma Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by AstraZeneca Plc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Bayer AG, H2 2018
  • Fallopian Tube Cancer - Pipeline by BeiGene Ltd, H2 2018
  • Fallopian Tube Cancer - Pipeline by Biocon Ltd, H2 2018
  • Fallopian Tube Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2018
  • Fallopian Tube Cancer - Pipeline by Boston Biomedical Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2018
  • Fallopian Tube Cancer - Pipeline by Celgene Corp, H2 2018
  • Fallopian Tube Cancer - Pipeline by Celldex Therapeutics Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Celsion Corp, H2 2018
  • Fallopian Tube Cancer - Pipeline by Celyad SA, H2 2018
  • Fallopian Tube Cancer - Pipeline by Clovis Oncology Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Corcept Therapeutics Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
  • Fallopian Tube Cancer - Pipeline by Eisai Co Ltd, H2 2018
  • Fallopian Tube Cancer - Pipeline by Eli Lilly and Co, H2 2018
  • Fallopian Tube Cancer - Pipeline by EpiThany Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Exelixis Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
  • Fallopian Tube Cancer - Pipeline by Fate Therapeutics Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Forty Seven Inc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2018
  • Fallopian Tube Cancer - Pipeline by Genmab A/S, H2 2018
  • Fallopian Tube Cancer - Pipeline by GlaxoSmithKline Plc, H2 2018
  • Fallopian Tube Cancer - Pipeline by Gradalis Inc, H2 2018

List of Figures

  • Number of Products under Development for Fallopian Tube Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Top 10 Routes of Administration, H2 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2018, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.

Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 14, 71, 46, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 7 and 1 molecules, respectively.

Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Fallopian Tube Cancer - Overview
  • Fallopian Tube Cancer - Therapeutics Development
  • Fallopian Tube Cancer - Therapeutics Assessment
  • Fallopian Tube Cancer - Companies Involved in Therapeutics Development
  • Fallopian Tube Cancer - Drug Profiles
  • Fallopian Tube Cancer - Dormant Projects
  • Fallopian Tube Cancer - Discontinued Products
  • Fallopian Tube Cancer - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research